Description
Overview PT-141 is a research-grade cyclic heptapeptide melanocortin receptor agonist supplied in intranasal research format for controlled laboratory use. It is intended for in vitro and analytical work examining melanocortin-receptor activation and central signaling-response models.
Research Background & Mechanistic Focus Current research use centers on melanocortin-receptor activation and central signaling-response models, comparative presentation or formulation behavior where applicable, and controlled experimental models designed to evaluate compound-specific signaling activity within non-clinical laboratory systems.
Structural Information Classification: Cyclic heptapeptide melanocortin receptor agonist Form: Intranasal research format Catalog Strengths: Single catalog strength
Research Applications Used in controlled laboratory settings for receptor-signaling models, comparative pathway analysis, presentation or stability work where applicable, and other non-clinical analytical workflows consistent with authorized research use.
Specifications Research-grade material supplied in intranasal research format. Intended for controlled laboratory handling and comparative format evaluation only.
Handling & Use Conditions Handle sealed intranasal research format units with standard laboratory PPE. Keep the container tightly sealed between uses and protect the material from heat, light, and cross-contamination during laboratory handling.
Storage & Stability Store refrigerated according to laboratory protocol, protected from light and unnecessary environmental exposure. Keep the container sealed when not in use to support formulation stability during the study period.
Sourcing Statement RawBiotix research compounds are sourced through U.S.-based supply and verified through independent analytical testing. Minimum 98% purity. Certificates of Analysis available upon request.
Disclaimer For laboratory research use only. Not for human consumption, therapeutic, or diagnostic purposes.
Reviews
There are no reviews yet.